These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16204659)

  • 1. Tirofiban plus sirolimus-eluting stent vs abciximab plus bare-metal stent.
    De Luca L; Sardella G
    JAMA; 2005 Oct; 294(13):1617; author reply 1617-8. PubMed ID: 16204659
    [No Abstract]   [Full Text] [Related]  

  • 2. Tirofiban plus sirolimus-eluting stent vs abciximab plus bare-metal stent.
    Osman F; Qaisar S; El Gaylani N; Pitt M
    JAMA; 2005 Oct; 294(13):1616-7; author reply 1617-8. PubMed ID: 16204658
    [No Abstract]   [Full Text] [Related]  

  • 3. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial.
    Valgimigli M; Percoco G; Malagutti P; Campo G; Ferrari F; Barbieri D; Cicchitelli G; McFadden EP; Merlini F; Ansani L; Guardigli G; Bettini A; Parrinello G; Boersma E; Ferrari R;
    JAMA; 2005 May; 293(17):2109-17. PubMed ID: 15870414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.
    Valgimigli M; Campo G; Percoco G; Bolognese L; Vassanelli C; Colangelo S; de Cesare N; Rodriguez AE; Ferrario M; Moreno R; Piva T; Sheiban I; Pasquetto G; Prati F; Nazzaro MS; Parrinello G; Ferrari R;
    JAMA; 2008 Apr; 299(15):1788-99. PubMed ID: 18375998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study.
    Valgimigli M; Campo G; Arcozzi C; Malagutti P; Carletti R; Ferrari F; Barbieri D; Parrinello G; Percoco G; Ferrari R
    J Am Coll Cardiol; 2007 Jul; 50(2):138-45. PubMed ID: 17616297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
    Garg S; Sarno G; Serruys PW; Rodriguez AE; Bolognese L; Anselmi M; De Cesare N; Colangelo S; Moreno R; Gambetti S; Monti M; Bristot L; Bressers M; Garcia-Garcia HM; Parrinello G; Campo G; Valgimigli M;
    JACC Cardiovasc Interv; 2011 Jan; 4(1):66-75. PubMed ID: 21251631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
    Valgimigli M; Campo G; Malagutti P; Anselmi M; Bolognese L; Ribichini F; Boccuzzi G; de Cesare N; Rodriguez AE; Russo F; Moreno R; Biondi-Zoccai G; Penzo C; Díaz Fernández JF; Parrinello G; Ferrari R
    JACC Cardiovasc Interv; 2011 Jan; 4(1):51-62. PubMed ID: 21251629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tirofiban or abciximab and sirolimus-eluting or bare metal uncoated stents in primary percutaneous coronary intervention for acute myocardial infarction: results of MULTISTRATEGY trial].
    Iavelov IS
    Kardiologiia; 2008; 48(7):59-61. PubMed ID: 18789031
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention.
    Herrmann HC; Swierkosz TA; Kapoor S; Tardiff DC; DiBattiste PM; Hirshfeld JW; Klugherz BD; Kolansky DM; Magness K; Valettas N; Wilensky RL
    Am J Cardiol; 2002 Jun; 89(11):1293-7. PubMed ID: 12031731
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban).
    Assali AR; Salloum J; Sdringola S; Moustapha A; Ghani M; Hale S; Schroth G; Fujise K; Anderson HV; Smalling RW; Rosales OR
    Am J Cardiol; 2001 Oct; 88(8):884-6, A6. PubMed ID: 11676953
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study.
    Wijnbergen I; Helmes H; Tijssen J; Brueren G; Peels K; van Dantzig JM; Van' t Veer M; Koolen JJ; Pijls NH; Michels R
    JACC Cardiovasc Interv; 2012 Mar; 5(3):313-22. PubMed ID: 22440498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The MULTISTRATEGY study].
    Danzi GB; Marzocchi A
    G Ital Cardiol (Rome); 2009 Jun; 10(6):353-7. PubMed ID: 19603605
    [No Abstract]   [Full Text] [Related]  

  • 14. Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction: design and rationale for the MULTI-STRATEGY trial.
    Valgimigli M; Bolognese L; Anselmi M; Campo G; Rodriguez AE; de Cesare N; Cohen DJ; Sheiban I; Colangelo S; Pasquetto G; Hamon M; Vranckx P; Ferrario M; Prati F; Agostoni P; Malagutti P; Arcozzi C; Parrinello G; Vassanelli C; Ferrari R; Percoco G
    Am Heart J; 2007 Jul; 154(1):39-45. PubMed ID: 17584549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiographic predictors of adverse outcomes in the modern interventional era.
    White CJ
    J Am Coll Cardiol; 2003 Sep; 42(6):989-90. PubMed ID: 13678917
    [No Abstract]   [Full Text] [Related]  

  • 16. Sex-specific benefits of sirolimus-eluting stent on long-term outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: insights from the Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study trial.
    Ferrante G; Presbitero P; Corrada E; Campo G; Bolognese L; Vassanelli C; Colangelo S; De Cesare N; E Rodriguez A; Bramucci E; Moreno R; Piva T; Sheiban I; Pasquetto G; Prati F; Nazzaro MS; Ferrari R; Valgimigli M
    Am Heart J; 2012 Jan; 163(1):104-11. PubMed ID: 22172443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Will blocking the platelet save the diabetic?
    King SB; Mahmud E
    Circulation; 1999 Dec 21-28; 100(25):2466-8. PubMed ID: 10604881
    [No Abstract]   [Full Text] [Related]  

  • 18. Platelet glycoprotein IIB/IIIA receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention.
    Ronner E; Dykun Y; van den Brand MJ; van der Wieken LR; Simoons ML
    Eur Heart J; 1998 Nov; 19(11):1608-16. PubMed ID: 9857912
    [No Abstract]   [Full Text] [Related]  

  • 19. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanical reperfusion: treat well, treat on time too.
    Montalescot G
    Lancet; 2008 Aug; 372(9638):509-10. PubMed ID: 18707968
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.